

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

## **PW MEDTECH GROUP LIMITED**

### **普华和顺集团公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1358)**

### **PROFIT ALERT**

This announcement is made by PW Medtech Group Limited (the “**Company**” and together with its subsidiaries, collectively the “**Group**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

Based on a preliminary review by the Company’s management on the unaudited consolidated management accounts of the Group for the six months ended June 30, 2022 (the “**Management Accounts**”), the board (the “**Board**”) of directors (the “**Directors**”) of the Company wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that:

- (i) the Group is expected to record a significant decrease in its profit for the six months ended June 30, 2022, comparing to the profit for the corresponding period in 2021, as the one-off gain of approximately RMB731.8 million recorded on disposal of the shares of China Biologic Products Holdings in the first half of 2021 (the “**One-off Disposal Gain in 2021**”) did not recur in 2022; and
- (ii) after excluding the impact of the One-off Disposal Gain in 2021 from the Group’s financial results for the six months ended June 30, 2021, the Group is expected to record an increase of at least approximately 80% in its net profit for the six months ended June 30, 2022 as compared to the corresponding period in 2021.

Based on currently available information, such significant increase in net profit excluding the impact of the One-off Disposal Gain in 2021 was mainly attributable to (i) the financial effects brought by a newly acquired subsidiary of the Company, namely Sichuan Ruijian Medical Technology Co. Ltd. (四川睿健醫療科技股份有限公司); and (ii) the net foreign exchange gain for the six months ended June 30, 2022 caused by the fluctuation of the exchange rate for the US dollar deposits denominated in RMB.

The Company is in the course of finalising the unaudited condensed consolidated interim financial results of the Group for the six months ended June 30, 2022. The information contained in this announcement is only based on a preliminary assessment by the management of the Company on the Management Accounts, which have not been confirmed, reviewed or audited by the Company’s auditors and may be subject to adjustments.

Details of the Group's financial results and performance for the six months ended June 30, 2022 will be disclosed in the interim results announcement of the Company which is expected to be announced by the end of August 2022. Shareholders and potential investors are advised to read the Group's interim results announcement of the Company when published.

**Shareholders and potential investors should exercise cautious when dealing in the shares of the Company.**

By order of the Board  
**PW Medtech Group Limited**  
**Yue'e Zhang**  
*Chairwoman*

Hong Kong, August 24, 2022

*As at the date of this announcement, the Board comprises one executive Director, namely, Ms. Yue'e Zhang; two non-executive Directors, namely, Mr. Jiang Liwei and Mr. Lin Junshan; and three independent non-executive Directors, namely, Mr. Wang Xiaogang, Mr. Chen Geng and Ms. Wang Fengli.*